Literature DB >> 12755958

Cell signalling and gene expression mediated by RET tyrosine kinase.

K Kurokawa1, K Kawai, M Hashimoto, Y Ito, M Takahashi.   

Abstract

Germline mutations of the RET proto-oncogene cause multiple endocrine neoplasia (MEN) 2A or 2B by different mechanisms. As is the case for other receptor tyrosine kinases, mutant RET recruits a variety of signalling molecules via phosphorylated tyrosine residues present in the kinase domain and carboxy-terminal tail. As we previously reported, the signaling via phosphorylated tyrosine 1062 plays a crucial role in the transforming activities of both RET-MEN2A and RET-MEN2B mutant protein. Interestingly, this single tyrosine residue represents a binding site for several signalling molecules including SHC, Enigma, SNT/FRS2, DOK and IRS1 and is responsible for activation of the RAS/ERK, PI3-K/AKT, JNK, p38MAPK and ERK5 signalling pathways. Amongst these, the PI3-K/AKT and JNK pathways appeared to be more strongly activated in the cells expressing RET-MEN2B than in the cells expressing RET-MEN2A, suggesting the possibility that these pathways may be involved in the disease phenotype. In addition, RET is alternatively spliced to produce three isoforms and the splicing site is present just downstream of tyrosine 1062. These isoforms play different roles for the tumour development associated with MEN 2 or the development of the kidney and the enteric nervous system. Moreover, using differential display analysis, we identified several genes whose expression is highly induced by RET-MEN2B mutant proteins. The differential gene expression by RET-MEN2A and RET-MEN2B may also be important for the development of their phenotypes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755958     DOI: 10.1046/j.1365-2796.2003.01167.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  7 in total

1.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

2.  Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.

Authors:  Matthew J Smith; W Rod Hardy; James M Murphy; Nina Jones; Tony Pawson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

3.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

4.  Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.

Authors:  Thomas J Musholt; Julia Hanack; Christoph Brehm; Reinhard von Wasielewski; Petra B Musholt
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

5.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

6.  Protein kinase Czeta and glycogen synthase kinase-3beta control neuronal polarity in developing rodent enteric neurons, whereas SMAD specific E3 ubiquitin protein ligase 1 promotes neurite growth but does not influence polarity.

Authors:  Bhupinder P S Vohra; Ming Fu; Robert O Heuckeroth
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

7.  A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.

Authors:  Maria Carmela Cantisani; Alessia Parascandolo; Merja Perälä; Chiara Allocca; Vidal Fey; Niko Sahlberg; Francesco Merolla; Fulvio Basolo; Mikko O Laukkanen; Olli Pekka Kallioniemi; Massimo Santoro; Maria Domenica Castellone
Journal:  Oncotarget       Date:  2016-05-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.